Carbetocin -Retrophin

Drug Profile

Carbetocin -Retrophin

Alternative Names: CYP-2001

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Retrophin
  • Class Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder

Most Recent Events

  • 26 Aug 2010 Cypress Bioscience acquires patent and technology rights for intranasal carbetocin from Marina Biotech
  • 25 Aug 2010 Marina Biotech is seeking to divest its nasal drug delivery programmes
  • 01 Apr 2010 MDRNA acquires Cequent Pharmaceuticals and is renamed Marina Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top